Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Raymond Perez, MD, Rachid Baz, MD, Paul G. Richardson, Kenneth C. Anderson, MD, Peter Sabbatini, PhD, Clifford Dilea, Pina M. Cardarelli, PhD, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, Pamela S. Becker, MD PhD

Blood (2014) 124 (21): 3483.

https://doi.org/10.1182/blood.V124.21.3483.3483

Published: 2014

Journal Articles

Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination

Aldo M Roccaro, MD PhD, Antonio Sacco, BS, Michele Moschetta, MD, Yuji Mishima, PhD, Patricia Maiso, PhD, Daisy Huynh, MPS, Marco Chiarini, MSc, Pina M. Cardarelli, PhD, Lewis Cohen, MD MS, Michelle Kuhne, PhD, Irene M. Ghobrial, MD

Blood (2014) 124 (21): 4709.

https://doi.org/10.1182/blood.V124.21.4709.4709

Published: 2014

Journal Articles

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD PhD, James M. Foran, MD, Jessica K. Altman, MD, Abdulraheem Yacoub, MD MB, Januario E. Castro, MD, Peter Sabbatini, PhD, Clifford Dilea, Mark Wade, Guan Xing, PhD, Andres Gutierrez, MD PhD, Lewis Cohen, MD MS, B. Douglas Smith, MD

Blood (2014) 124 (21): 386.

https://doi.org/10.1182/blood.V124.21.386.386

Published: 2014

Journal Articles

BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial

Manoj Kumar Kashyap, PhD, Carlos I. Amaya-Chanaga, MD, Harrison Jones, BS, Eiman A. AlMahasnah, MBBS, Michael Y. Choi, MD, Michelle R. Kuhne, PhD, Lewis Cohen, MD, MS, Peter Sabbatini, PhD, Thomas J. Kipps, MD, PhD, Pina M. Cardarelli, Ph.D., Januario E. Castro, M.D.

Blood (2013) 122 (21): 4190.

https://doi.org/10.1182/blood.V122.21.4190.4190

Published: 2013

Journal Articles

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Sylvia Chien, Lauren E. Beyerle, Brent L. Wood, MD, PhD, Elihu H. Estey, MD, Frederick R. Appelbaum, MD, Pina M. Cardarelli, Ph.D., Peter Sabbatini, PhD, Suresh Shelat, MD-PhD, Lewis Cohen, MD, MS, Pamela S. Becker, MD, PhD

Blood (2013) 122 (21): 3882.

https://doi.org/10.1182/blood.V122.21.3882.3882

Published: 2013

Journal Articles

BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.

Manoj Kumar Kashyap, PhD, Deepak Kumar, PhD, Harrison Jones Jones, BS, Michael Y. Choi, MD, Johanna Melo-Cardenas, B.Sc, Michelle R. Kuhne, PhD, Peter Sabbatini, PhD, Lewis Cohen, MD, MS, Suresh Shelat, MD-PhD, Pina M Cardarelli, Ph.D., Thomas J. Kipps, MD, PhD, Januario E. Castro, M.D.

Blood (2012) 120 (21): 2887.

https://doi.org/10.1182/blood.V120.21.2887.2887

Published: 2012

Journal Articles

CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells

Aldo M Roccaro, MD, PhD, Antonio Sacco, BS, Michelle R. Kuhne, PhD, Abdel Kareem Azab, PhD, BSPharm, Patricia Maiso, PhD, Feda Azab, BPharm, Salomon Manier, MD, Yosra Aljaway, BS, Michaela R Reagan, PhD, Lewis Cohen, MD, MS, Pina M Cardarelli, Ph.D., Irene M. Ghobrial, MD

Blood (2012) 120 (21): 4009.

https://doi.org/10.1182/blood.V120.21.4009.4009

Published: 2012

Journal Articles

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Anti Tumor Activity In Vivo

Michelle R. Kuhne, PhD, Tanya Mulvey, Sharline Chen, Chin Pan, Ph.D., Colin Chong, Wafa Niekro, Tom Kempe, Ph.D., Karla A. Henning, Ph.D., Lewis Cohen, MD, MS, Alan Korman, Ph.D., Pina M Cardarelli, Ph.D.

Blood (2011) 118 (21): 1543.

https://doi.org/10.1182/blood.V118.21.1543.1543

Published: 2011

NARROW

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

BMS-936564 (Anti-CXCR4 Antibody) Induces Specific Leukemia Cell Mobilization and Objective Clinical Responses In CLL Patients Treated Under a Phase I Clinical Trial

Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

BMS-936564 (MDX1338): A Fully Human Anti-CXCR4 Antibody Induces Apoptosis in an in Vitro Model of Stromal – Leukemia Cell Interaction for Chronic Lymphocytic Leukemia.

CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Anti Tumor Activity In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only